Company overview
CellVec is a GMP-certified Contract Development and Manufacturing Organisation (CDMO) specializing in custom viral vectors for gene therapy and cellular therapies. Based in Singapore, the company provides lentiviral vector manufacturing services for preclinical and clinical applications, leveraging proprietary technology to achieve improved yields and process consistency. CellVec serves pharmaceutical and biotech clients developing cell-based immunotherapies and gene therapies for cancer and genetic diseases.
Cellvec is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include viral vector cdmo, lentiviral vector manufacturing, gene therapy manufacturing, gmp viral vector, cell therapy cdmo.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Cellvec include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://cellvec.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- viral vector cdmo, lentiviral vector manufacturing, gene therapy manufacturing, gmp viral vector, cell therapy cdmo
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What types of viral vectors does CellVec manufacture?
- CellVec specializes in custom lentiviral vectors for preclinical and clinical applications. The company has developed a proprietary lentivirus-based vector platform designed to overcome technological bottlenecks in upscale production and deliver improved yields with high process consistency.
- What regulatory certifications and compliance standards does CellVec maintain?
- CellVec is a certified GMP (Good Manufacturing Practice) CDMO with a state-of-the-art facility built to comply with international manufacturing standards. The company is qualified to manufacture viral vectors for both translational research and commercial gene therapy applications.
- What is CellVec's geographic location and regional significance?
- CellVec is based in Singapore and is recognized as Southeast Asia's first GMP-compliant CDMO for viral vector manufacturing. The company has established strategic partnerships with international institutions, including Australia's Peter MacCallum Cancer Centre, to support cell-based immunotherapy development.
- What therapeutic applications does CellVec support?
- CellVec manufactures viral vectors for gene therapies and cellular therapies targeting genetic diseases and cancer. The company specifically supports clients developing cell-based immunotherapies and advanced therapeutic medicinal products (ATMPs).
- What manufacturing challenges does CellVec address?
- CellVec's platform technology is designed to overcome existing bottlenecks in viral vector upscale production, which is characterized as unpredictable, complex, and challenging for traditional biologics manufacturers. The company emphasizes process-driven design and consistency to enable clinical and commercial-scale manufacturing.
Related editorial coverage
- ASGCT 2026: Gene Therapy Manufacturing Innovations Emerge
- ASGCT 2026: Gene Therapy Manufacturing Advances to Watch
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
